Adverse events of interest were thromboembolic adverse events ( six -LSB- @ % -RSB- patients receiving @F-PCC vs seven -LSB- @ % -RSB- patients receiving plasma ) , fluid overload or similar cardiac events ( three -LSB- @ % -RSB- patients vs @ -LSB- @ % -RSB- patients ) , and late bleeding events ( three -LSB- @ % -RSB- patients vs four -LSB- @ % -RSB- patients ) .